Retatrutide does not hold a UK marketing authorisation as of 2026 and falls under the MHRA's (Medicines and Healthcare products Regulatory Agency) general framework for unlicensed medicinal products and investigational compounds, not as a licensed therapeutic [7]
For a side-by-side look at how GLP-3 RT (retatrutide) differs from other GLP-pathway research compounds, see our retatrutide vs tirzepatide comparison.
[2] Research shows that GLP-1 medication can help lower blood sugar levels by increasing insulin and reducing the secretion of a hormone that raises blood sugar levels
Carretero-Krug, A., Montero-Bravo, A., Morais-Moreno, C., Puga, A
Instead: Semaglutide creates a sustained energy deficit by reducing appetite and calorie intake